Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.04 – $0.12
3% from low
Exchange
OTC Link
OS
Borrow rate
5.07%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $1.7K | $2.4K | $1.1K | $495 | $223 | $69 | $46 |
| Gross profit | $0 | −$1.7K | −$2.4K | −$1.1K | −$495 | −$223 | −$69 | −$46 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $2.3M | $2.4M | $650.0K | $179.9K | $622.7K | $384.9K | $3.0K | $2.5M |
| Operating income | −$6.6M | −$4.7M | −$4.9M | −$6.7M | −$3.3M | −$2.3M | −$2.0M | −$5.6M |
| EBITDA | $0 | −$4.6M | −$4.9M | −$2.8M | −$3.3M | −$2.3M | −$2.0M | −$5.6M |
| Net income | −$6.2M | −$4.9M | −$7.8M | −$6.3M | −$5.2M | −$2.5M | −$2.6M | −$4.7M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -0.41 | -0.32 | -0.24 | -0.11 | -0.07 | -0.03 | -0.03 | -0.03 |
Annual figures · source: Financial Modeling Prep
HEMOSTEMIX INC
No one on the platform currently holds HMTXF.
No tracked institution reports a position in HMTXF as of their last filing.
| Execution date | Ratio |
|---|---|
| 2020-12-30 | 1-for-20reverse |
No one on the platform has traded HMTXF yet.
| $34M |
| — |
| INTIInhibitor Therapeutics, Inc. | $0.09 | +0.00% | $16M | — |
| LVCLFAlgorae Pharmaceuticals Limited | $0.01 | +17.90% | $16M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.